The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions.
At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, and plenty more. (Here’s a link to last year’s roundup.)
Existing platforms are being expanded upon to cater to more patients, while new platforms like implants and all-in-one systems are being designed to manage diabetes in new and innovative ways.
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang say the space is gearing up for some serious movement down the line.
“Diabetes tech continues to move quickly and is being helped by favorable coverage, label expansions, and growing awareness,” the analysts wrote. “We expect market growth rates for both CGMs and pumps to remain well above most of medtech, but given timelines for future product launches, we see this as a development year, with potential for market shifts in 2026 or beyond.”
Here are the standout stories from this year’s American Diabetes Association Scientific Sessions in Chicago:
Get the full story at our sister site, Drug Delivery Business News.
